CanSino Biologics Inc (CJH) — Cash Flow-to-Debt Ratio
CanSino Biologics Inc (CJH) has a Cash Flow-to-Debt Ratio of -0.10x as of June 2023, meaning its operating cash flow of €-392.00 Million could theoretically repay 0% of its total liabilities (€3.93 Billion) in one year. See CJH financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CanSino Biologics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for CanSino Biologics Inc across 10 annual periods. For the full cash flow conversion analysis, see CanSino Biologics Inc (CJH) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for CanSino Biologics Inc (2016–2025)
Year-by-year debt coverage analysis for CanSino Biologics Inc. Check CJH cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | €77.86 Million | €2.22 Billion | ▲ +163.2% |
| 2024 | -0.06x | €-168.79 Million | €3.05 Billion | ▲ +75.6% |
| 2023 | -0.23x | €-916.25 Million | €4.03 Billion | ▲ +48.2% |
| 2022 | -0.44x | €-1.85 Billion | €4.22 Billion | ▼ -171.1% |
| 2021 | 0.62x | €2.05 Billion | €3.33 Billion | ▲ +219.3% |
| 2020 | -0.52x | €-349.93 Million | €677.22 Million | ▼ -5.2% |
| 2019 | -0.49x | €-154.25 Million | €313.98 Million | ▼ -16.6% |
| 2018 | -0.42x | €-123.64 Million | €293.56 Million | ▼ -93.8% |
| 2017 | -0.22x | €-56.30 Million | €259.03 Million | ▲ +29.4% |
| 2016 | -0.31x | €-34.38 Million | €111.70 Million | — |